Received Jun 30, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | UNK | — |
Four patients had intervals of up to 2 years; This non-serious case was reported by a other health professional and described the occurrence of drug dose administration interval too long in a specified number of patients who received Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix (received first dose up to 2 years ago). On an unknown date, the patients received the 2nd dose of Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too long (Verbatim: Four patients had intervals of up to 2 years). The outcome of the drug dose administration interval too long was not applicable. Additional Information: GSK Receipt Date: 20-JUN-2025 Health care professional noted approximately 4 patients had longer than recommended interval between dose 1 and dose 2 of Shingrix. Reporter stated that four patients had intervals of up to 2 years. No specific patient details given and there were no other adverse effects noted. The patients received 2nd dose of Shingrix, later than the recommended interval, which led to lengthening of vaccinations schedule.